Literature DB >> 15701325

[Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study].

Antonia Andreu1, Juan Ignacio Alós, Miguel Gobernado, Francesc Marco, Manuel de la Rosa, José Antonio García-Rodríguez.   

Abstract

INTRODUCTION: Knowledge of antimicrobial susceptibility patterns is required to prescribe empirical therapy and formulate guidelines for the treatment of community-acquired urinary tract infections. This multicenter study assesses the etiology and antimicrobial susceptibility of the main community-acquired uropathogens in Spain.
METHODS: Between March and July 2002, a prospective, multicenter study was conducted in 15 microbiology laboratories located in nine autonomous regions. Each laboratory used its standard methods for sample processing and culture, bacterial identification and susceptibility testing.
RESULTS: A total of 2724 isolates were recovered from outpatients with lower urinary tract infections. The most frequent pathogen found was Escherichia coli (73%), followed by Proteus spp. (7.4%), Klebsiella spp. (6.6%) and Enterococcus spp. (4.8%). The susceptibility rates of E. coli were 97.9% for fosfomycin, 95.8% for cefixime, 94.3% for nitrofurantoin, 90.8% for amoxicillin-clavulanic acid and 77.2% for ciprofloxacin. E. coli resistance to fluoroquinolones was significantly higher in men (28.9% vs. 19% in women; P < 0.001), elderly patients (33.7% in 80 years or older vs. 7.1% in 40 years or younger; P < 0.001), complicated infections (24.8% vs. 13.7% in non-complicated; P < 0.001) and some regions (> 32% in Andalusia, Aragon and Castilla-Leon vs. 9.2% in Galicia).
CONCLUSIONS: E. coli was the main uropathogen in outpatients. Almost all E. coli isolates were susceptible to fosfomycin, cefixime and nitrofurantoin. Overall fluoroquinolone resistance was near 23%, but this rate varied significantly according to sex, age, type of urinary infection, and geographic region. This information should be considered when empirical therapy is recommended or prescribed in Spain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701325     DOI: 10.1157/13070401

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  14 in total

1.  Anti-microbial stewardship for urinary tract infection.

Authors:  C Sheehan; N Chew
Journal:  Ir J Med Sci       Date:  2005 Oct-Dec       Impact factor: 1.568

2.  In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.

Authors:  M de Cueto; L López; J R Hernández; C Morillo; A Pascual
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil.

Authors:  David Sevillano; Lorenzo Aguilar; Luis Alou; María-José Giménez; Martha Torrico; Natalia González; Fabio Cafini; María-Teresa Relaño; Pilar Coronel; José Prieto
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

4.  Oral therapy for urinary tract infections in infants aged 3 to 12 months.

Authors:  G Claret Teruel; J J García García; M Fernández de Sevilla Estrach; E Corrales Magin; V Trenchs Sáinz de la Maza; A Rodríguez Arráez; J A Camacho Díaz; C Luaces Cubells
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-01       Impact factor: 3.267

5.  Is Streptococcus bovis a urinary pathogen?

Authors:  M Matesanz; D Rubal; I Iñiguez; R Rabuñal; F García-Garrote; A Coira; M J García-País; J Pita; A Rodriguez-Macias; M J López-Álvarez; M P Alonso; J Corredoira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-22       Impact factor: 3.267

6.  Trends and risk factors of extended-spectrum beta-lactamase urinary tract infection in Chinese children: a nomogram is built and urologist should act in time.

Authors:  Jiandong Lu; Lin Wang; Yi Wei; Shengde Wu; Guanghui Wei
Journal:  Transl Pediatr       Date:  2022-06

7.  In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.

Authors:  Lorenzo Drago; Lucia Nicola; Roberto Mattina; Elena De Vecchi
Journal:  BMC Microbiol       Date:  2010-04-21       Impact factor: 3.605

8.  Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide.

Authors:  Nuno Cerca; Tomás Maira-Litrán; Kimberly K Jefferson; Martha Grout; Donald A Goldmann; Gerald B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-19       Impact factor: 11.205

9.  A Cohort Study of Risk Factors That Influence Empirical Treatment of Patients with Acute Pyelonephritis.

Authors:  Pau Bosch-Nicolau; Vicenç Falcó; Belén Viñado; Antonia Andreu; Oscar Len; Benito Almirante; Carles Pigrau
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

10.  Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study.

Authors:  Pilar Retamar; María Dolores López-Prieto; Clara Nátera; Marina de Cueto; Enrique Nuño; Marta Herrero; Fernando Fernández-Sánchez; Angel Muñoz; Francisco Téllez; Berta Becerril; Ana García-Tapia; Inmaculada Carazo; Raquel Moya; Juan E Corzo; Laura León; Leopoldo Muñoz; Jesús Rodríguez-Baño; Fernando Rodríguez-López; María V García; Verónica Fernández-Galán; Alfonso del Arco; María J Pérez-Santos; Antonio Sánchez Porto; Manuel Torres-Tortosa; Andrés Martín-Aspas; Ascensión Arroyo; Carolina García-Figueras; Federico Acosta; Carmen Florez; Petra Navas; Trinidad Escobar-Lara
Journal:  BMC Infect Dis       Date:  2013-07-24       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.